Opening book details…
Can I read A Proposal to Elevate the Status of Troponin and B-Type Natriuretic Peptides as Atherosclerotic Cardiovascular Disease Risk Enhancers on EtoBox?
A Proposal to Elevate the Status of Troponin and B-Type Natriuretic Peptides as Atherosclerotic Cardiovascular Disease Risk Enhancers by Vijay Nambi is a book available to read on EtoBox.
What is A Proposal to Elevate the Status of Troponin and B-Type Natriuretic Peptides as Atherosclerotic Cardiovascular Disease Risk Enhancers about?
Current guidelines for management of blood presHF, and mortality across multiple population-based sure (BP) and lipids to prevent atherosclerotic carstudies; (2) stronger association with incident ASCVD diovascular disease (ASCVD) recommend use of events than most currently recommended risk enhancers; (3) clinical trial data demonstrating that these biorisk scores based on traditional cardiovascular risk factors to guide the selection and intensity of drug therapy. Recmarkers identify individuals who derive larger absolute risk reduction from preventive therapies; and (4) wide ognizing that features not included in these risk scores may modify ASCVD risk, “risk-enhancing factors,” such availability of accurate clinical assays for measurement (Table).as pregnancy complications, inflammatory disorders, low ankle–brachial index, elevated hs-CRP (high-sensitivity C-reactive protein), elevated lipoprotein(a), and high coronary calcium score have been recommended to augCOMPARISON OF hs-cTn AND NPs WITHment risk assessment in borderline or intermediate-risk CURRENT RISK ENHANCERSindividuals. The most recently developed (Predicting Risk of Cardiovascular Disease Events) risk equatio
- Author
- Vijay Nambi
- Published
- 2025
- Language
- EN
More by Vijay Nambi
Browse all works by Vijay Nambi
Similar books
- Atherosclerotic Cardiovascular Disease — Ksenija Pesek (2011)
- Natriuretic Peptides in Health and Disease — T. Geoffrey Flynn (auth.), Willis K. Samson PhD, Ellis R. Levin MD (1997)
- Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease — Hokyou Lee MD PhD & Xiaoning Huang PhD & Sadiya S. Khan MD MSc & Dasom Son BS & Hyeok-Hee Lee MD PhD & Eun-Jin Kim MS & Donald M. Lloyd-Jones MD ScM & Hyeon Chang Kim MD PhD & Philip Greenland MD (2025)
- Metabolic Risk for Cardiovascular Disease — Eckel R. (2011)
- Molecular Basis of Cardiovascular Diseases: Implications of Natriuretic Peptides — Massimo Volpe Speranza Rubattu (2019)
- Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease — Galli, Mattia; Cortellini, Gabriele; Occhipinti, Giovanni; Rossini, Roberta; Romano, Antonino; Angiolillo, Dominick J. (2024)